Effects of miR-152 on Cell Growth Inhibition, Motility Suppression and Apoptosis Induction in Hepatocellular Carcinoma Cells

  • Dang, Yi-Wu (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) ;
  • Zeng, Jing (Department of Ophthalmology, First Affiliated Hospital, Guangxi Medical University) ;
  • He, Rong-Quan (Department of Medical Oncology, First Affiliated Hospital, Guangxi Medical University) ;
  • Rong, Min-Hua (Research Department, Affiliated Cancer Hospital, Guangxi Medical University) ;
  • Luo, Dian-Zhong (Department of Pathology, First Affiliated Hospital, Guangxi Medical University) ;
  • Chen, Gang (Department of Pathology, First Affiliated Hospital, Guangxi Medical University)
  • Published : 2014.06.30


Background: miR-152 is involved in the genesis and development of several malignancies. However, its role in HCC has not been fully clarified. The aim of this study was to investigate the clinicopathological significance of miR-152 and its effect on the malignant phenotype of HCC cells. Methods: miR-152 expression was detected using real-time quantitative RT-PCR in 89 pairs of HCC formalin-fixed paraffin-embedded and their adjacent tissues. Functionally, in vitro effects and mechanisms of action of miR-152 on proliferation, viability, caspase activity, apoptosis and motility were explored in HepG2, HepB3 and SNU449 cells, as assessed by spectrophotometry, fluorimetry, fluorescence microscopy, wound-healing and Western blotting, respectively. Results: miR-152 expression in HCC was downregulated remarkably compared to that in adjacent hepatic tissues. miR-152 levels in groups of advanced clinical stage, larger tumor size and positive HBV infection, were significantly lower than in other groups. A miR-152 mimic could suppress cell growth, inhibit cell motility and increase caspase activity and apoptosis in HCC cell lines. Furthermore, Western blotting showed that the miR-152 mimic downregulated Wnt-1, DNMT1, ERK1/2, AKT and TNFRS6B signaling. Intriguingly, inverse correlation of TNFRF6B and miR-152 expression was found in HCC and bioinformatics confirmed that TNFRF6B might be a target of miR-152. Conclusions: Underexpression of miR-152 plays a vital role in hepatocarcinogenesis and lack of miR-152 is related to the progression of HCC through deregulation of cell proliferation, motility and apoptosis. miR-152 may act as a tumor suppressor miRNA by also targeting TNFRSF6B and is therefore a potential candidate biomarker for HCC diagnosis, prognosis and molecular therapy.


  1. Yang M, Chen G, Dang Y, Luo D (2010). Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci, 115, 232-7.
  2. Woo HH, Laszlo CF, Greco S, et al (2012). Regulation of colony stimulating factor-1 expression and ovarian cancer cell behavior in vitro by miR-128 and miR-152. Mol Cancer, 11, 58.
  3. Xiang Y, Ma N, Wang D, et al (2014). MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene, 33, 378-86.
  4. Yamazaki K, Masugi Y, Sakamoto M (2011). Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. Dig Dis, 29, 284-8.
  5. Zhang J, Wang R, Ma YY, Chen LQ, Jin BH, Yu H, et al. (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac J Cancer Prev, 14, 6427-31.
  6. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, et al. (2012). Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep, 27, 447-54.
  7. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, et al. (2013). miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. The Prostate, 73, 1082-9.
  8. Rong M, Chen G, Dang Y (2013a). Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro. BMC Cancer, 13, 21.
  9. Liu DZ, Ander BP, Tian Y, et al (2012). Integrated analysis of mRNA and microRNA expression in mature neurons, neural progenitor cells and neuroblastoma cells. Gene, 495, 120-7.
  10. Mollaie HR, Monavari SH, Arabzadeh SA, et al (2013). RNAi and miRNA in viral infections and cancers. Asian Pacific J Cancer Prev, 14, 7045-56.
  11. Papagiannakopoulos T, Kosik KS (2008). MicroRNAs: regulators of oncogenesis and stemness. BMC Med, 6, 15.
  12. Rong M, He R, Dang Y, et al (2013b). Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues. Ups J Med Sci, 119, 19-24.
  13. Song H, Liu Y, Pan J, et al (2013). Expression profile analysis reveals putative prostate cancer-related microRNAs. Genet Mol Res, 12, 4934-43.
  14. Song YX, Yue ZY, Wang ZN, et al (2011). MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer, 10, 1.
  15. Sun J, Lu HQ, Wang X, et al (2013). MicroRNAs in Hepatocellular Carcinoma: Regulation, Function, and Clinical Implications. Sci World J, 2013, 924206.
  16. Tsai MC, Spitale RC, Chang HY (2011). Long intergenic noncoding RNAs: new links in cancer progression. Cancer Res, 71, 3-7.
  17. Tsuruta T, Kozaki K, Uesugi A, et al (2011). miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res, 71, 6450-62.
  18. Huang S, Xie Y, Yang P, et al (2014). HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 Cells. PloS one, 9, e81730.
  19. Hiroki E, Akahira J, Suzuki F, Nagase S, Ito K, Suzuki T, et al. (2010). Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas. Cancer Sci, 101, 241-9.
  20. Hu L, Chen G, Yu H, Qiu X (2010). Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinoma. Hepatol Int, 4, 423-32.
  21. Huang J, Wang Y, Guo Y, et al (2010). Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology, 52, 60-70.
  22. Hunt EA, Goulding AM, Deo SK (2009). Direct detection and quantification of microRNAs. Anal Biochem, 387, 1-12.
  23. Karabork A, Kaygusuz G, Ekinci C (2010). The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma. Pathol Res Pract, 206, 572-7.
  24. Kohler CU, Bryk O, Meier S, et al (2013). Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochemical and biophysical research communications, 438, 48-53.
  25. Kudo M (2011). Hepatocellular carcinoma in 2011 and beyond: from the pathogenesis to molecular targeted therapy. Oncology, 81, 1-10.
  26. Lichner Z, Fendler A, Saleh C, et al (2013). MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem, 59, 1595-603.
  27. Chen G, Noor A, Kronenberger P, et al (2013b). Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One, 8, e59708.
  28. Chen G, Kronenberger P, Teugels E, et al (2011). Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells. Biol Proced Online, 13, 1-8.
  29. Chen G, Kronenberger P, Teugels E, et al (2012). Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. BMC Med, 10, 28.
  30. Chen G, Kronenberger P, Teugels E, et al (2013a). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9.
  31. Chen G, Umelo IA, Lv S, et al (2013c). miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One, 8, e60317.
  32. Chen Y, Song Y, Wang Z, et al (2010c). Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J Gastrointest Surg, 14, 1170-9.
  33. Chen Y, Song YX, Wang ZN (2013d). The microRNA-148/152 family: multi-faceted players. Molecular cancer, 12, 43.
  34. Dang Y, Luo D, Rong M, et al (2013). Underexpression of miR-34a in hepatocellular carcinoma and its contribution towards enhancement of proliferating inhibitory effects of agents targeting c-MET. PloS one, 8, e61054.
  35. Das S, Foley N, Bryan K, et al. (2010). MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation. Cancer Res, 70, 7874-81.
  36. Azizi M, Teimoori-Toolabi L, Arzanani MK, et al (2014). MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines. Cancer Biol Ther, 15, 419-27.
  37. Braconi C, Huang N, Patel T (2010). MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology, 51, 881-90.
  38. Chen G, Luo DZ, Liu L, et al (2006). Hepatic local microenvironmental immune status in hepatocellular carcinoma and cirrhotic tissues. West Indian Med J, 55, 403-8.
  39. Chen G, Dang YW, Luo DZ, et al (2008a). Expression of heparanase in hepatocellular carcinoma has prognostic significance: a tissue microarray study. Oncol Res, 17, 183-9.
  40. Chen G, Luo D (2008b). Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India, 21, 275-8.
  41. Chen G, Rong M, Luo D (2010a). TNFRSF6B neutralization antibody inhibits proliferation and induces apoptosis in hepatocellular carcinoma cell. Pathol Res Pract, 206, 631-41.
  42. Chen G, Kronenberger P, Umelo IA, et al (2010b). Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction. Anal Biochem, 398, 266-8.

Cited by

  1. MiR-1297 Regulates the Growth, Migration and Invasion of Colorectal Cancer Cells by Targeting Cyclo-oxygenase-2 vol.15, pp.21, 2014,
  2. Ki-67 is a Valuable Prognostic Factor in Gliomas: Evidence from a Systematic Review and Meta-analysis vol.16, pp.2, 2015,
  3. Upregulation and Clinicopathological Significance of Long Non-coding NEAT1 RNA in NSCLC Tissues vol.16, pp.7, 2015,
  4. MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance vol.20, pp.1, 2015,
  5. MicroRNA-141 Is a Biomarker for Progression of Squamous Cell Carcinoma and Adenocarcinoma of the Lung: Clinical Analysis of 125 Patients vol.235, pp.3, 2015,
  6. Comprehensive Expression Profiling and Functional Network Analysis of p53-Regulated MicroRNAs in HepG2 Cells Treated with Doxorubicin vol.11, pp.2, 2016,
  7. An Encapsulation of Gene Signatures for Hepatocellular Carcinoma, MicroRNA-132 Predicted Target Genes and the Corresponding Overlaps vol.11, pp.7, 2016,
  8. MicroRNA-152 inhibits cell proliferation, migration and invasion by directly targeting MAFB in nasopharyngeal carcinoma vol.15, pp.2, 2016,
  9. MicroRNA-152 inhibits tumor cell growth by directly targeting RTKN in hepatocellular carcinoma vol.37, pp.2, 2016,
  10. Circulating miR-148/152 family as potential biomarkers in hepatocellular carcinoma vol.37, pp.4, 2016,
  11. Cell-free microRNAs in blood and other body fluids, as cancer biomarkers vol.49, pp.3, 2016,
  12. Clinical value of miR-452-5p expression in lung adenocarcinoma: A retrospective quantitative real-time polymerase chain reaction study and verification based on The Cancer Genome Atlas and Gene Expression Omnibus databases vol.39, pp.5, 2017,
  13. Interest of variations in microRNA-152 and -122 in a series of hepatocellular carcinomas related to hepatitis C virus infection pp.13866346, 2017,
  14. Myc target gene, long intergenic noncoding RNA, Linc00176 in hepatocellular carcinoma regulates cell cycle and cell survival by titrating tumor suppressor microRNAs pp.1476-5594, 2017,
  15. Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation vol.16, pp.1, 2018,
  16. Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma vol.12, pp.1756-2848, 2019,